Dr Robin Young MBChB, MRCP, MSc, PhD
Weston Park Hospital
Tel: 0114 226 5000
I graduated from the University of Edinburgh in 1999. I moved to Sheffield in 2006 to undertake specialist medical oncology training, including three years as a Yorkshire Cancer Research clinical research fellow at the University of Sheffield. I was appointed a consultant medical oncologist at Weston Park Hospital, Sheffield in 2015. My clinical and research interests involve sarcoma and colorectal cancer. I am the principal investigator for Sheffield on a number of national and international clinical trials. My research interests focus on the role of the tumour microenvironment including the potential of vascular targeted therapy.
EORTC Soft Tissue and Bone Sarcoma Group – Young Oncologist
Joint Steering Committee ECMC Combinations Alliance
Young R, Poyser C, Crack L, Dockrell D, Bowman C, Billlingham L, Bower M, Westwell S, Leahy M, Woll P. A UK national phase I/II clinical trial of a MEK1/2 inhibitor combined with highly active anti-retroviral therapy for HIV-associated Kaposi’s sarcoma. Eur J Cancer. 2015. 51:S699.
Grünwald V, Litiere S, Young RJ, Messiou C, Michela L, Wardelmann E, Van der Graaf W, Gronchi A, Judson I. Absence of progression, not extent of remission defines prognosis in soft tissue sarcoma – an analysis of the EORTC 62012 study. Eur J Cancer. 2015. 51:S688.
Young RJ, Natukunda A, Litiere S, Woll PJ, Wardelmann E, van der Graaf WTA. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven EORTC Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014. 50(18):3178-86.
Young RJ, Fernando M, Hughes D, Brown N, Woll P. Angiogenic growth factor expression in benign and malignant vascular tumours. Exp Mol Pathol. 2014. 97(1):148-53.
Young RJ, Woll PJ, Staton CA, Reed MWR, Brown NJ. Vascular-targeted agents for the treatment of angiosarcoma. Cancer Chemother & Pharmacol. 2014. 3(2):259-70.
Young RJ, Coleman RE. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol. 2013. 9(5): 633-43.
Best J, Young R, Ddamba J, Danson SJ, Fisher F, Foran B, Hatton M, Lee C, Mohanamurali J, Woll PJ. Blood transfusion requirements of NSCLC patients receiving chemotherapy in the BTOG2 trial. Lung Cancer. 2013. 79(Suppl1):S15-16.
Young RJ*, Tin AW*, Brown NJ, Jitlal M, Lee SM, Woll PJ. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br J Cancer. 2012. 106(6): 1153-1159.
Young RJ, Reed MWR. Anti-angiogenic therapy: Concept to Clinic. Microcirculation. 2012.19(2): 115-125.
Young RJ, Tin A, Brown NJ, Staton CA, Lee SM, Jitlal M, Woll PJ. Serum biomarkers in lung cancer patients from two clinical trials of chemotherapy with or without thalidomide. J Thorac Oncol. 2011. 6(Suppl2):S1058.
Young RJ, Woll PJ, Staton CA, Reed MW, Brown NJ. Targeting VEGF in Human Angiosarcoma Cell Lines in Vitro. European J Cancer 2011. 47: S665.
Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol 2010; 11: 983-91.
Young R, Hancock B. The presentation, diagnosis and staging of renal cell carcinoma. In: Hancock B (ed.) Lectures in Targeted Cancer Therapy: Advanced Renal Cell Carcinoma. Published by Current Medical Group. 2008: 6-10.
Simpson A, Young R, Delany S, Harvey C, Dady P. Maintaining ABVD Dose Intensity with an abbreviated course of GCSF in patients with Hodgkin’s Lymphoma. Ann Oncol 2005; 16: 5(S): 544.